Does Peter Attia recommend CoQ10 (Ubiquinol/Ubiquinone)?
Peter Attia recommends CoQ10 (Ubiquinol/Ubiquinone) in some contexts, but has also raised cautions.
Published research rates it moderate evidence. Of Peter Attia's 107 tracked claims, 42 are supported or partially supported by studies on PubMed.
Evidence last reviewed May 2026
Peter Attia on CoQ10 (Ubiquinol/Ubiquinone) — 107 claims
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The provided research corpus does not contain studies directly addressing the three specific populations Attia identifies (mitochondrial dysfunction patients, statin users, and older individuals) as p…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 retrieved studies directly address the specific clinical recommendation of ubiquinol (100–200 mg with a fat-containing meal) for statin users over age 60. The available literature cover…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 retrieved studies directly address the specific claim: ubiquinol supplementation at 100–200 mg with a fatty meal for statin users over age 60. The available literature covers CoQ10 in c…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 retrieved studies directly address the clinical scenario described in Attia's claim: ubiquinol supplementation (100–200 mg with a fat-containing meal) specifically for statin users over…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The provided research abstracts contain no extractable key findings, populations, or limitations, making it impossible to directly evaluate Attia's claim against the cited literature. The studies list…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The expert's claim identifies three populations (mitochondrial dysfunction patients, statin users, older individuals) as primary CoQ10 beneficiaries. The provided literature includes a review on disor…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The provided research corpus does not contain studies directly evaluating CoQ10 supplementation outcomes stratified by the three populations Attia identifies: those with mitochondrial dysfunction, sta…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
None of the 10 studies provided include extractable key findings, populations, or limitations, making it impossible to directly assess Attia's claim. The available literature includes reviews and meta…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the provided studies contain extractable key findings, populations, or limitations data, making it impossible to directly evaluate Attia's specific recommendation. While several relevant publi…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
The recommendation to use ubiquinol (reduced CoQ10) for statin users over 60 has partial support from the literature. PMID 30371340, a meta-analysis of RCTs on CoQ10 and statin-induced myopathy, indic…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
For patients over 60 who are on statins, he recommends ubiquinol 100 to 200 mg taken with a fat-containing meal.
The rationale for CoQ10 supplementation in statin users has biological plausibility — statins inhibit the mevalonate pathway, reducing endogenous CoQ10 synthesis — and PMID 30371340 (meta-analysis of…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 listed studies provide key findings, population data, or limitations that can be directly assessed against Attia's specific recommendation. While several studies are relevant in topic (…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
While the provided literature includes reviews and meta-analyses on CoQ10 supplementation (PMIDs 33325173, 24389208, 34129891), CoQ10 metabolism disorders (PMID 32933108), and neurological application…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
The provided research abstracts lack extractable key findings, populations, and limitations, making direct comparison impossible. While several relevant CoQ10 reviews are listed (PMIDs 33325173, 24389…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The claim about statin users is most directly supported: the meta-analysis (PMID: 30371340) specifically investigated CoQ10 for statin-induced myopathy in RCTs, and PMID: 32933108 and PMID: 24389208 c…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
For patients over 60 who are on statins, the recommendation is ubiquinol 100 to 200 milligrams taken with a fat-containing meal.
The evidence partially supports the claim. PMID 30371340 (meta-analysis of RCTs) directly addresses CoQ10 supplementation for statin-induced myopathy but notes results remain inconclusive. PMID 379716…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trial results on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy are conflicting, with some studies showing benefit and others not.
The meta-analysis by PMID 30371340, an updated meta-analysis of randomized controlled trials on CoQ10 and statin-induced myopathy, directly addresses this claim. Its key finding notes that 'whether Co…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature includes reviews on CoQ10 for cardiovascular disease, neurological conditio…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided research abstracts contain the Q-SYMBIO trial data or directly address CoQ10 supplementation in heart failure patients with the specific outcomes cited (cardiovascular mortalit…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 retrieved studies directly address the Q-SYMBIO trial or CoQ10 supplementation in heart failure patients with cardiovascular mortality endpoints. The retrieved literature focuses on ooc…
Claims are extracted from publicly available podcasts and videos, attributed to their source, and compared against PubMed research. This is educational information only — consult a healthcare provider before starting any supplement.
Back to Peter Attia